0
0
New Delhi, Aug 6 (IANS) – Indian researchers at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), an autonomous institute under the Department of Science and Technology, are exploring a pioneering therapeutic strategy that leverages microRNAs (miRNAs) to target Alzheimer’s disease—a neurodegenerative disorder that is the world’s leading cause of dementia.
Alzheimer’s disease (AD) is marked by the buildup of abnormal protein clumps in the brain, leading to progressive memory loss and cognitive decline. Current treatments offer only temporary symptom management, and recently introduced antibody-based drugs provide limited benefits for patients. The JNCASR team is focusing on miRNAs—small, non-coding RNA molecules renowned for regulating gene expression across vital biological pathways. Notably, the 2023 Nobel Prize in Physiology or Medicine was awarded for the discovery of RNA-based mechanisms, further underscoring the significance of this research avenue.
The Indian scientists have studied alterations in miRNA profiles in the brains of AD patients and assessed their promise as both precise diagnostic biomarkers and innovative drug targets. Since miRNAs are capable of influencing multiple disease pathways simultaneously, they offer a unique opportunity to interrupt the progression of AD at a molecular level. These molecules are stable in bodily fluids, making them especially suitable for early, non-invasive diagnosis via blood or cerebrospinal fluid tests.
If successful, the strategy could accelerate clinical drug development and provide a dual benefit: enabling clinicians to diagnose AD in its earliest stages and laying the foundation for genuinely disease-modifying therapies.
JNCASR’s research builds on global evidence that certain miRNAs can distinguish AD from other neurodegenerative conditions and may reflect disease severity early, well before the appearance of advanced symptoms. However, the field remains early in its translational journey, with further validation required in large-scale clinical trials.
Disclaimer: The research discussed above is ongoing and at an early stage. Current findings do not constitute a cure for Alzheimer’s disease, and no miRNA-based therapy has yet been approved for clinical use. Readers should consult healthcare professionals for medical guidance and await further peer-reviewed results before considering changes in diagnosis or treatment approaches.
